<DOC>
	<DOCNO>NCT00382031</DOCNO>
	<brief_summary>The purpose study investigate zalutumumab combination Best Supportive Care ( BSC ) superior BSC non-curable patient head neck cancer</brief_summary>
	<brief_title>Zalutumumab Patients With Non-curable Head Neck Cancer</brief_title>
	<detailed_description>This open parallel group trial . Patients randomize 2:1 manner receive either treatment zalutumumab combination Best Supportive Care ( BSC ) BSC . Patients randomize treatment zalutumumab combination BSC receive weekly infusion zalutumumab start load dose ( 8mg/kg ) follow weekly maintenance dos disease progression , intercurrent illness prevent administration , unacceptable toxicity patient decision . After Visit 2 patient evaluate presence skin rash prior infusion allow dose titration . Individual dose titration patient develop grade 2 skin rash apply . The maximum dose use study 16 mg/kg .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Males Females age â‰¥ 18 year 2 . Confirmed diagnosis , initially relapse , squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx , consider incurable standard therapy 3 . Failure least one course standard platinumbased chemotherapy 1 . Three chemotherapy regimen platinumbased chemotherapy 2 . Prior treatment EGFr antibodies and/or EGFr small molecule inhibitor 3 . Past current malignancy SCCHN , except certain cancer disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>